CN109549931B - Anti-tumor medicine freeze-dried powder and preparation method thereof - Google Patents
Anti-tumor medicine freeze-dried powder and preparation method thereof Download PDFInfo
- Publication number
- CN109549931B CN109549931B CN201811560877.0A CN201811560877A CN109549931B CN 109549931 B CN109549931 B CN 109549931B CN 201811560877 A CN201811560877 A CN 201811560877A CN 109549931 B CN109549931 B CN 109549931B
- Authority
- CN
- China
- Prior art keywords
- freeze
- excipient
- water
- active component
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention relates to the field of pharmaceutical chemistry, and discloses freeze-dried powder of an anti-tumor drug and a preparation method thereof. The freeze-dried powder of the anti-tumor drug contains a drug active component and an excipient, wherein the mass ratio of the drug active component to the excipient is 1: 0.5-8, wherein the active component of the medicine is 1, 4-diamine naphthalene derivative shown in formula (I) and pharmaceutically acceptable salt and solvate thereof. The freeze-dried powder of the anti-tumor drug can inhibit VEGF, can be used for treating and/or preventing diseases related to epidermal growth factor receptor tyrosine kinase in mammals, and can also be used for treating tumor diseases.
Description
Technical Field
The invention relates to the field of pharmaceutical chemistry, in particular to freeze-dried powder of an anti-tumor drug and a preparation method thereof.
Background
Recent clinical and basic medical research results have demonstrated that tumor development and metastasis are dependent on the formation of new blood vessels. Tumor angiogenesis is the result of the interaction of tumor cells, vascular endothelial cells, vascular extracellular matrix, and the like. Among them, the biological function of vascular endothelial growth factor VEFG (vascular endothelial growth factor) is crucial in angiogenesis.
Most cell growth factor receptors contain the peptide chain sequence of tyrosine kinases, and overexpression or activation of different tyrosine kinase receptors is seen in many tumors. These receptors are further divided into several families according to the similarity of peptide chain sequences and their structural features: 1. the epidermal growth factor receptor family, including EGFR, HER-2, HER-3, HER-4, etc., the high expression of which is common in epithelial cell tumors; 2. the insulin receptor family, including insulin receptor, insulin-like growth factor receptor (IGF-R), and insulin-related receptor (IRR), among others, is commonly high expressed in blood cancers; 3. platelet derived growth factor receptor family (PDGFR) including PDGFR-alpha, PDEFR-beta, CSF-1R, c-Kit, etc., which are commonly highly expressed in brain tumors, blood cancers; 4. fibroblast Growth Factor Receptors (FGFR), including FGFR-1, FGFR-2, FGFR-3, FGFR-4, and the like, which have important roles in angiogenesis; 5. vascular Endothelial Growth Factor Receptors (VEGFRs), including VEGFR-1, VEGFR-2, and VEGFR-3, are important positive regulators of angiogenesis.
VEFG is a growth factor that acts mainly on vascular endothelial cells, and has various functions of promoting endothelial cell proliferation, increasing microvascular permeability, inducing angiogenesis, and the like. The formation and development of tumors can be largely divided into two phases, namely the clonal proliferation phase of tumor cells and the subsequent phase in which angiogenesis promotes the continued growth of tumors. VEGF acts on the endothelial cells of the vascular network itself, and differentiates them to form new blood vessels. The new blood vessels not only provide a foundation for the material exchange of the tumor cells, but also can paracrine some cytokines to promote the proliferation of the tumor cells; meanwhile, as the wall structure of the new blood vessel is lack of integrity, the connection between endothelial cells is loose, the basement membrane has different thickness and is broken or damaged, and tumor cells are easy to enter the lumen of the blood vessel to cause blood invasion and metastasis. VEGF is therefore closely associated with tumor growth and metastasis. VEGF is detected in most tissues of healthy humans, but is expressed in very small amounts, and is highly expressed in many tumors (especially solid tumors), for example: liver cancer, brain tumor, breast cancer and kidney cancer tissues. Because of the dependence of growth and metastasis of solid tumors on new blood vessels, VEGF is a desirable target site for blocking the vascularization of solid tumors. VEGFR is a diffusible vascular endothelial specific mitogen and angiogenic growth factor receptor, plays a key role in physiological and pathological angiogenesis processes, and can inhibit endothelial cell apoptosis. The family includes VEGFR-1, VEGFR-2, VEGFR-3. It is currently believed that binding of VEGF to VEGFR-2, which causes VEGFR-2 to form a dimer, induces tyrosine kinase mediated phosphorylation and further activates the associated downstream signaling pathways.
In recent years, various VEGFR-targeted drugs such as Sunitinib, Sorafenib, Pazopanib, etc. have been approved for the treatment of various tumors. Although these tumor angiogenesis inhibitors have great advantages, the practical application still has the problems of weak dependence of part of tumors on angiogenesis, drug resistance, adverse reaction and toxicity caused by mutation and compensation of tumor signal transduction. Therefore, it is necessary to develop a small molecule protein kinase inhibitor with stronger selectivity, higher activity and less toxicity.
Disclosure of Invention
The invention aims to provide freeze-dried powder of an anti-tumor medicament and a preparation method thereof.
The invention provides freeze-dried powder of an anti-tumor drug, which contains a pharmaceutically active component and an excipient, wherein the mass ratio of the pharmaceutically active component to the excipient is 1: 0.5 to 8, wherein the active component of the medicine is 1, 4-diamine naphthalene derivative shown in formula (I) and pharmaceutically acceptable salt and solvate thereof,
wherein L is1And L2Each selected from O, S and NH;
n is 0, 1, 2, 3, 4 or 5;
R1selected from hydrogen, C1-C8Alkyl and C3-C7A cycloalkyl group;
R2selected from hydrogen, C1-C8Alkyl, substituted C1-C8Alkyl radical, C3-C7Cycloalkyl, substituted C3-C7Cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl;
R3selected from hydrogen, C1-C8Alkyl and C3-C7A cycloalkyl group;
R4is selected from C3-C7Heterocycloalkyl, substituted C3-C7Heterocycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.
Preferably, in formula (I), R1Is hydrogen, R2Selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl.
Preferably, in formula (I), L is O, n is 3, R3Selected from hydrogen, methyl and ethyl, R4Selected from morpholine, piperidine, pyrrolidine and piperazine.
Preferably, the 1, 4-diamine naphthalene derivative has the structural formula:
preferably, the mass ratio of the pharmaceutically active component to the excipient is 1: 0.8-2.
Preferably, the excipient is at least one of mannitol, glucose and lactose.
The invention also provides a preparation method for preparing the freeze-dried powder, which comprises the following steps:
(1) stirring the active pharmaceutical ingredient, the excipient and the water for injection until the active pharmaceutical ingredient, the excipient and the water for injection are completely dissolved to obtain a freeze-dried stock solution;
(2) pre-freezing the freeze-dried stock solution at-10 to-30 ℃ for 1 to 3 hours, vacuumizing to 5 to 30Pa after freezing, heating to-2 to-8 ℃ at the speed of 1 to 3 ℃ per hour, carrying out sublimation drying treatment for 5 to 20 hours, heating to 5 to 40 ℃ at the speed of 5 to 10 ℃ per hour, and carrying out resolution drying treatment for 5 to 10 hours.
Preferably, the volume ratio of the total amount of the pharmaceutically active component and the excipient to the water for injection is 5-20: 100, more preferably 8 to 15: 100.
the freeze-dried powder contains 1, 4-diamine naphthalene derivative and pharmaceutically acceptable salt and solvate thereof, can be used for treating tumor diseases and can also be used for treating and/or preventing diseases related to epidermal growth factor receptor tyrosine kinase in mammals.
Detailed Description
The following describes in detail specific embodiments of the present invention. It should be understood that the detailed description and specific examples, while indicating the present invention, are given by way of illustration and explanation only, not limitation.
The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value, and such ranges or values should be understood to encompass values close to those ranges or values. For ranges of values, between the endpoints of each of the ranges and the individual points, and between the individual points may be combined with each other to give one or more new ranges of values, and these ranges of values should be considered as specifically disclosed herein.
The freeze-dried powder of the anti-tumor medicament contains a medicinal active component and an excipient.
In the freeze-dried powder of the anti-tumor drug, the mass ratio of the drug active component to the excipient can be 1: 0.5 to 8, preferably 1: 0.8-2.
In the invention, the active component of the medicine is 1, 4-diamine naphthalene derivative shown in formula (I) and pharmaceutically acceptable salt and solvate thereof,
wherein L is1And L2Each selected from O, S and NH, preferably O;
n is 0, 1, 2, 3, 4 or 5;
R1selected from hydrogen, C1-C8Alkyl and C3-C7A cycloalkyl group;
R2selected from hydrogen, C1-C8Alkyl, substituted C1-C8Alkyl (e.g. haloalkyl), C3-C7Cycloalkyl, substituted C3-C7Cycloalkyl (e.g. halocycloalkyl), aryl, substituted aryl(e.g., haloaryl), heteroaryl, and substituted heteroaryl (e.g., haloheteroaryl);
R3selected from hydrogen, C1-C8Alkyl and C3-C7A cycloalkyl group;
R4is selected from C3-C7Heterocycloalkyl, substituted C3-C7Heterocycloalkyl (e.g., haloheterocycloalkyl), aryl, substituted aryl (e.g., haloaryl), heteroaryl, and substituted heteroaryl (e.g., haloheteroaryl).
In a preferred embodiment, in formula (I), R1Is hydrogen, R2Selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl.
In another preferred embodiment, in formula (I), L is O, n is 3, and R is3Selected from hydrogen, methyl and ethyl, R4Selected from morpholine, piperidine, pyrrolidine and piperazine.
In a specific embodiment, the 1, 4-diaminonaphthalene derivative has the structural formula:
the method for preparing the 1, 4-diaminonaphthalene derivative represented by the formula (I) may include the steps of:
(a) dealkylation of the compound represented by the formula (1) to obtain a compound represented by the formula (2);
(b) subjecting a compound represented by formula (2) to a nucleophilic substitution reaction to obtain a compound represented by formula (3);
(c) introducing a hydroxyl group into the compound represented by the formula (3) in the presence of tert-butyl hydroperoxide and potassium hydroxide to obtain a compound represented by the formula (4);
(d) subjecting a compound represented by formula (4) to a substitution reaction to obtain a compound represented by formula (5);
(e) subjecting the compound represented by the formula (5) to an affinity substitution reaction with an amino substituent to obtain a compound represented by the formula (6);
(f) subjecting a compound represented by formula (6) to a hydrogenation reduction reaction to obtain a target compound;
wherein X is halogen, L1、L2、n、R1、R2、R3And R4Are as defined above.
In step (a), preferably, the dealkylation is carried out in the presence of L-methionine, the solvent used is methanesulfonic acid, and the reaction temperature is 85-95 ℃.
In step (b), preferably, the nucleophilic substitution reaction is carried out under basic conditions at a reaction temperature of 75-85 ℃.
Preferably, the reaction of step (c) is carried out in the presence of t-butanol hydroperoxide and potassium hydroxide at a reaction temperature of 0 ± 5 ℃.
In one embodiment, the process route for the preparation of the 1, 4-diaminonaphthalene derivatives of formula (I) is as follows:
the specific preparation process comprises the following steps: taking 6, 7-dimethoxy-1-nitronaphthalene as a starting material, demethylating in a methanesulfonic acid solvent in the presence of L-methionine, carrying out Williamson reaction with 3-chloropropyl morpholine under an alkaline condition, introducing a hydroxyl group into an obtained intermediate in the presence of tert-butyl hydroperoxide and potassium hydroxide, carrying out substitution reaction with phosphorus pentachloride, carrying out affinity substitution with various amino substitutes, and carrying out hydrogenation reduction to obtain a target compound.
Description of the terms
The "alkyl group" in the present invention means a straight or branched saturated hydrocarbon group, preferably a C1-C6 alkyl group, more preferably a C1-C3 alkyl group, and preferably a C1-C3 alkyl group is a methyl group, an ethyl group, a propyl group or an isopropyl group.
"halogen" in the context of the present invention means fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine, most preferably chlorine.
"haloalkyl", "halocycloalkyl", "haloaryl", "haloheteroaryl" and "haloheterocycloalkyl" in the context of the present invention refer to alkyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl, respectively, substituted with at least one halogen. The haloalkyl group may be, for example, a halogenated C1-C6 alkyl group.
"solvate" as used herein refers to a compound that is associated with a solvent, typically by a solvolysis reaction. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, ether, and the like. Suitable solvates include pharmaceutically acceptable solvates and also include both stoichiometric and non-stoichiometric solvates. If water, the solvate is referred to as a hydrate, e.g., a monohydrate, a dihydrate, a trihydrate, and the like.
The "pharmaceutically acceptable salts" of the present invention are those which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.
"neoplastic disorders" of the invention include, but are not limited to, acoustic neuroma, adenocarcinoma, adrenal gland cancer, anal cancer, angiosarcoma (e.g., lymphangiosarcoma, lymphangial sarcoma, angiosarcoma), appendiceal cancer, benign monoclonal gammopathy, cholangiocarcinoma, bladder cancer, breast cancer, brain cancer, bronchial cancer, carcinoid tumor, cervical cancer, choriocarcinoma, chordoma, colorectal cancer, connective tissue cancer, esophageal cancer, eye cancer, gastric cancer, head and neck cancer, oral cancer, throat cancer, hematopoietic cancer (e.g., leukemia: acute lymphocytic leukemia ALL, acute myelogenous leukemia AML, chronic myelogenous leukemia CML, and chronic lymphocytic leukemia CLL), lymphoma, renal cancer, liver cancer, lung cancer (small cell lung cancer SCLC, non-small cell lung cancer NSCLC), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD) (chronic myelogenous leukemia CML, MDS), Chronic neutrophilic leukemia CNL, hypereosinophilic syndrome HES), osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, vaginal cancer, and the like.
In the present invention, the excipient may be a conventional choice in the art. In a specific embodiment, the excipient is at least one of mannitol, glucose, and lactose.
The invention also provides a method for preparing the freeze-dried powder of the anti-tumor drug, which comprises the following steps:
(1) stirring the active pharmaceutical ingredient, the excipient and the water for injection until the active pharmaceutical ingredient, the excipient and the water for injection are completely dissolved to obtain a freeze-dried stock solution;
(2) pre-freezing the freeze-dried stock solution at-10 to-30 ℃ for 1 to 3 hours, vacuumizing to 5 to 30Pa after freezing, heating to-2 to-8 ℃ at the speed of 1 to 3 ℃ per hour, carrying out sublimation drying treatment for 5 to 20 hours, heating to 5 to 40 ℃ at the speed of 5 to 10 ℃ per hour, and carrying out resolution drying treatment for 5 to 10 hours.
In the method of the present invention, the volume ratio of the total amount of the pharmaceutically active ingredient and the excipient to the water for injection may be 5 to 20: 100, preferably 8 to 15: 100.
the present invention will be described in detail below by way of examples, but the scope of the present invention is not limited thereto.
Preparation example 1
(1) Preparation of 3-methoxy-5-nitro-2-naphthol
Dissolving 6, 7-dimethoxy-1-nitronaphthalene (4.66g, 20mmol) and L-methionine (2.98g, 20mmol) in 38.4g of methanesulfonic acid (400mmol), stirring and reacting for 8h under the reflux heating condition of an oil bath at 90 ℃, after the TLC detection reaction is completed, neutralizing with a saturated sodium bicarbonate solution until no bubbles appear, detecting with a pH test paper to be neutral or weakly alkaline, extracting the aqueous phase for 3 times with ethyl acetate, combining the ethyl acetate phases, washing with saturated sodium chloride water for three times, drying with anhydrous magnesium sulfate, filtering, evaporating to dryness under reduced pressure, and performing column chromatography to obtain a yellow powdery solid (1.18g, yield: 27%).
(2) Preparation of 4- (3- ((3-methoxy-5-nitronaphthalene-2-) oxy) propyl) morpholine
Dissolving 3-methoxy-5-nitro-2-naphthol (2.19g, 10mmol), anhydrous potassium carbonate (1.80g, 13mmol) and anhydrous potassium iodide (0.166g, 1mmol) in 25ml of N, N-Dimethylformamide (DMF), stirring uniformly, adding 3-chloropropyl morpholine (1.80g, 11mmol) into the reaction solution, stirring under reflux and heating conditions for 3h, detecting by TLC after the reaction is complete, cooling to room temperature, adding 150ml of distilled water into the reaction solution, extracting the water phase 3 times with ethyl acetate, combining ethyl acetate, washing three times with water, washing three times with saturated sodium chloride aqueous solution, drying with anhydrous magnesium sulfate, filtering, drying the filtrate under reduced pressure, evaporating to dryness, and performing column chromatography to obtain yellow powdery solid (3.18g, yield: 92%).
(3) Preparation of 6-methoxy-7- (3-morpholinopropyloxy) -4-nitro-1-naphthol
4- (3- ((3-methoxy-5-nitronaphthalene-2-) oxy) propyl) morpholine (1.73g, 5mmol) was dissolved in 13ml of dimethyl sulfoxide (DMSO), to this solution was added potassium hydroxide (1.2g, 20mmol) dissolved in 5ml of water at 0-5 ℃ and after stirring for 5 minutes, 2ml of DMSO-t-butanol hydroperoxide (0.54g, 6mmol) was added to the solution. After stirring at room temperature for 6 hours, the reaction mixture was slowly poured into 100ml of water, the aqueous phase was extracted with dichloromethane three times, the dichloromethane phases were combined, washed with saturated aqueous sodium chloride solution three times, dried over anhydrous sodium sulfate, filtered, evaporated to dryness, and subjected to column chromatography to obtain a yellow powder (yield: 78%).
(4) Preparation of 4- (3- (8-chloro-3-methoxy-5-nitronaphthalene-2-oxy) propyl) morpholine
6-methoxy-7- (3-morpholinopropyloxy) -4-nitro-1-naphthol (5.79g, 16mmol) was dissolved in phosphorus oxychloride (45ml, 490mmol), and stirred under reflux for 3 h. After cooling, the reaction mixture was slowly poured into a 2mol/L sodium carbonate solution (450ml) in an ice-water bath, stirred, suction-filtered, the filter cake was washed with warm water, and dried to give a yellowish solid (yield: 65%).
(5) 4-fluorophenyl- (6-methoxy-7- (3-morpholinopropoxy)) -4-nitronaphthyl-1-amino
Para-fluoroaniline (1.78g, 16mmol), 4- (3- (8-chloro-3-methoxy-5-nitronaphthalene-2-oxy) propyl) morpholine (3.80g, 10mmol) and potassium carbonate (4.1g, 30mmol) in 50ml of dmf were stirred and heated to 60 ℃, reacted for 5h, cooled to room temperature, filtered, and the solution was purified with (DCM/MeOH ═ 20:1) to give 1.54g (yield: 61%) of a yellow solid product, which showed the following nuclear magnetic hydrogen spectrum data.
1H-NMR(400MHz,DMSO-d6)，1.80-1.85(m,2H)；2.25-2.38(t，2H)；2.32-2.49(t，4H)；3.52-3.62(t，4H)；3.75(s，3H)；4.00(s，1H)；6.22-6.30(dd，1H)；6.32-6.39(dd，1H)；6.42-6.49(d，2H)；6.75-6.89(d,2H)；6.98(s,2H)。
(6) N' -4-fluorophenyl- (6-methoxy-7- (3-morpholinopropoxy)) -4-naphthyl-1, 4-diamine
4-fluorophenyl- (6-methoxy-7- (3-morpholinopropoxy)) -4-nitronaphthyl-1-ammonia (0.455g, 1mmol) was dissolved in 10ml of methanol, and 0.1g of palladium on carbon was added to the solution at room temperature. Stirring at room temperature for 12 hours under the condition of hydrogen gas with ten atmospheres, filtering by using kieselguhr to remove palladium carbon after the reaction is finished, washing by using methanol for three times, and carrying out column chromatography to obtain a compound 1 which is a white solid, has the yield of 82 percent and has the following nuclear magnetic hydrogen spectrum data.
1H-NMR(400MHz,DMSO-d6)，1.81-1.86(m,2H)；2.28-2.34(t，2H)；2.39-2.51(t，4H)；3.59-3.67(t，4H)；3.72(s，3H)；4.01(s，1H)；4.06(s，2H)；6.25-6.31(dd，1H)；6.35-6.38(dd，1H)；6.45-6.48(d，2H)；6.74-6.86(d,2H)；6.83(s,2H)。
In a similar manner to example 1, compounds 2 to 6 were obtained, and the structural formulae and nuclear magnetic hydrogen spectrum data thereof are shown in the following table.
Test example 1
In vitro target compounds were tested for activity in inhibiting cancer cell proliferation in vitro.
The results of in vitro activity experiments on the target compounds for inhibiting cancer cell proliferation are shown in table 1.
Materials: MD-MBA-231 breast cancer cell strain, tetramethyl azodicarbonamide MTT, 10% fetal calf serum and 96-pore plate.
The method comprises the following steps:
cell culture: the MD-MBA-231 breast cancer cell line is evenly blown and beaten by RPMI1640 culture solution containing 10% fetal calf serum and then is planted in a culture bottle at 37 ℃ and 5% CO2Incubating in a saturated humidity cell culture box, digesting by 0.25% trypsin when the cell density reaches 70% -90%, and then carrying out passage.
Cell growth assay (MTT method): the MD-MBA-231 cell suspension was adjusted to 5X 104/mL and seeded in 96-well plates (100. mu.L/well) at 5000 cells/well. After plating for 4h, 100. mu.L of medium containing different concentrations of the compound was added to each well and the wells were platedThe final concentrations of the compounds were: 100. and four duplicate wells are arranged at each concentration of 50, 25, 12.5 and 6.25 mu g/mL, the wells without cells are used as blank controls when reading, the wells without cells are used as negative controls, and sorafenib is used as a compound positive control. At 37 ℃ with 5% CO2After 48h incubation, 10. mu.L of 0.5% MTT staining solution was added to each well, and after further incubation for 4h, the plate wells were centrifuged at 2500rpm for 12min, and then the plate wells were discarded, and DMSO solution was added at 100. mu.L/well. Measuring the absorption value OD value of each hole at 570nm on a microplate reader, and calculating the cell growth inhibition rate according to the following formula:
according to the concentration of the compound and the corresponding inhibition rate, the IC of each compound is obtained by fitting a curve by using origin7.5 software50。
TABLE 1
As can be seen from the results in Table 1, the IC of the compound of the present invention on MD-MBA-231 breast cancer cells50The compound is equivalent to sorafenib in magnitude order, and some compounds are obviously superior to sorafenib.
Example 1
Accurately weighing 0.5g of compound 1 and 0.5g of mannitol in a sterile environment, placing in a clean preparation container, adding 4ml of water for injection, stirring until the mixture is completely dissolved, adding 5ml of water for injection, and uniformly stirring to obtain a freeze-dried stock solution.
Filling the freeze-drying stock solution into a 10ml tube glass bottle, half plugging, and transferring into a freeze dryer for freezing treatment, wherein the specific freeze-drying process comprises the following steps: quickly freezing the freeze-dried stock solution to-25 ℃, lasting for 2 hours, vacuumizing to 15Pa, heating to-5 ℃ at the speed of 2 ℃ per hour, carrying out sublimation drying treatment for 12 hours, heating to 20 ℃ at the speed of 8 ℃ per hour, carrying out desorption drying treatment for 8 hours, fully plugging, and capping to obtain the anti-tumor drug freeze-dried powder A1.
Example 2
Accurately weighing 0.3g of compound 2 and 0.6g of glucose in a sterile environment, placing in a clean preparation container, adding 4ml of water for injection, stirring until the water for injection is completely dissolved, then adding 5ml of water for injection, and uniformly stirring to obtain a freeze-dried stock solution.
Filling the freeze-drying stock solution into a 10ml tube glass bottle, half plugging, and transferring into a freeze dryer for freezing treatment, wherein the specific freeze-drying process comprises the following steps: quickly freezing the freeze-dried stock solution to-30 ℃, keeping the freeze-dried stock solution for 1.5 hours, vacuumizing to 20Pa, heating to-8 ℃ at the speed of 1 ℃ per hour, carrying out sublimation drying treatment for 16 hours, heating to 30 ℃ at the speed of 5 ℃ per hour, carrying out desorption drying treatment for 5 hours, fully plugging, and capping to obtain the anti-tumor drug freeze-dried powder A2.
Example 3
Accurately weighing 0.5g of compound 3 and 0.4g of lactose in a sterile environment, placing in a clean preparation container, adding 4ml of water for injection, stirring until the water for injection is completely dissolved, then adding 5ml of water for injection, and uniformly stirring to obtain a freeze-dried stock solution.
Filling the freeze-drying stock solution into a 10ml tube glass bottle, half plugging, and transferring into a freeze dryer for freezing treatment, wherein the specific freeze-drying process comprises the following steps: quickly freezing the freeze-dried stock solution to-20 ℃, lasting for 3 hours, vacuumizing to 10Pa, heating to-3 ℃ at the speed of 3 ℃ per hour, carrying out sublimation drying treatment for 16 hours, heating to 40 ℃ at the speed of 10 ℃ per hour, carrying out desorption drying treatment for 5 hours, fully plugging, and capping to obtain the anti-tumor drug freeze-dried powder A3.
Example 4
Accurately weighing 0.4g of compound 4 and 0.6g of mannitol in a sterile environment, placing in a clean preparation container, adding 4ml of water for injection, stirring until the mixture is completely dissolved, adding 5ml of water for injection, and uniformly stirring to obtain a freeze-dried stock solution.
Filling the freeze-drying stock solution into a 10ml tube glass bottle, half plugging, and transferring into a freeze dryer for freezing treatment, wherein the specific freeze-drying process comprises the following steps: quickly freezing the freeze-dried stock solution to-15 ℃, lasting for 3 hours, vacuumizing to 5Pa, heating to-8 ℃ at the speed of 1 ℃ per hour, carrying out sublimation drying treatment for 5 hours, heating to 10 ℃ at the speed of 5 ℃ per hour, carrying out desorption drying treatment for 10 hours, fully plugging, and capping to obtain the anti-tumor drug freeze-dried powder A4.
Example 5
Accurately weighing 0.5g of compound 5 and 0.7g of mannitol in a sterile environment, placing in a clean preparation container, adding 4ml of water for injection, stirring until the mixture is completely dissolved, adding 5ml of water for injection, and uniformly stirring to obtain a freeze-dried stock solution.
Filling the freeze-drying stock solution into a 10ml tube glass bottle, half plugging, and transferring into a freeze dryer for freezing treatment, wherein the specific freeze-drying process comprises the following steps: quickly freezing the freeze-dried stock solution to-10 ℃, lasting for 3 hours, vacuumizing to 10Pa, heating to-2 ℃ at the speed of 1 ℃ per hour, carrying out sublimation drying treatment for 20 hours, heating to 40 ℃ at the speed of 5 ℃ per hour, carrying out desorption drying treatment for 10 hours, fully plugging, and capping to obtain the anti-tumor drug freeze-dried powder A5.
Example 6
Accurately weighing 0.6g of compound 6 and 0.5g of mannitol in a sterile environment, placing in a clean preparation container, adding 4ml of water for injection, stirring until the mixture is completely dissolved, adding 5ml of water for injection, and uniformly stirring to obtain a freeze-dried stock solution.
Filling the freeze-drying stock solution into a 10ml tube glass bottle, half plugging, and transferring into a freeze dryer for freezing treatment, wherein the specific freeze-drying process comprises the following steps: quickly freezing the freeze-dried stock solution to-18 ℃, lasting for 3 hours, vacuumizing to 10Pa, heating to-3 ℃ at the speed of 1 ℃ per hour, carrying out sublimation drying treatment for 18 hours, heating to 30 ℃ at the speed of 5 ℃ per hour, carrying out desorption drying treatment for 10 hours, fully plugging, and capping to obtain the anti-tumor drug freeze-dried powder A6.
Test example
The freeze-dried powder of the antitumor drug prepared in the above example was subjected to the following stability tests:
(1) high temperature detection
45 bottles of the finished product of the example were randomly picked and placed in a drug stability testing box. Standing at 60 deg.C for 10 days, and taking samples of 0, 5, and 10 days to test various indexes including appearance, solubility and clarity. The results are detailed in table 2.
(2) High humidity detection
Randomly extracting 45 bottles of finished products of the examples, placing each bottle in a drug stability test box after each bottle is accurately weighed, placing the bottles for 10 days under the conditions of the temperature of 25 ℃ and the Relative Humidity (RH) of 90% +/-5%, and comparing sampling detection on the 5 th day and the 10 th day with samples on the 0 th day; the appearance, redissolution and clarity of the product were examined. The results are detailed in Table 3.
(3) Intense light detection
45 bottles of finished products of the examples are randomly selected, placed in a strong light stability test box of the medicine, placed for 10 days under the condition of the illumination of 4500 +/-500 Lx, sampled and detected on the 0 th, 5 th and 10 th days respectively, and the light stability of the products is examined by comparing indexes such as appearance property, redissolution property, clarity and the like. The results are detailed in Table 4.
TABLE 2
TABLE 3
TABLE 4
As can be seen from the results of tables 2-4 above, the lyophilized powder of an antitumor drug prepared by the method of the present invention has good high temperature stability, high humidity stability and stability under strong light irradiation.
The preferred embodiments of the present invention have been described above in detail, but the present invention is not limited thereto. Within the scope of the technical idea of the invention, many simple modifications can be made to the technical solution of the invention, including combinations of various technical features in any other suitable way, and these simple modifications and combinations should also be regarded as the disclosure of the invention, and all fall within the scope of the invention.
Claims (5)
1. The freeze-dried powder of the antitumor drug contains a pharmaceutically active component and an excipient, and is characterized in that the mass ratio of the pharmaceutically active component to the excipient is 1: 0.5-8, wherein the active component of the medicine is 1, 4-diamine naphthalene derivative and pharmaceutically acceptable salt and solvate thereof,
wherein, the structural formula of the 1, 4-diamine naphthalene derivative is as follows:
the excipient is at least one of mannitol, glucose and lactose.
2. The lyophilized powder of claim 1, wherein the mass ratio of the pharmaceutically active component to the excipient is 1: 0.8-2.
3. A method of preparing a lyophilized powder of claim 1 or 2, comprising the steps of:
(1) stirring the active pharmaceutical ingredient, the excipient and the water for injection until the active pharmaceutical ingredient, the excipient and the water for injection are completely dissolved to obtain a freeze-dried stock solution;
(2) pre-freezing the freeze-dried stock solution at-10 to-30 ℃ for 1 to 3 hours, vacuumizing to 5 to 30Pa after freezing, heating to-2 to-8 ℃ at the speed of 1 to 3 ℃ per hour, carrying out sublimation drying treatment for 5 to 20 hours, heating to 5 to 40 ℃ at the speed of 5 to 10 ℃ per hour, and carrying out resolution drying treatment for 5 to 10 hours.
4. The method according to claim 3, wherein the volume ratio of the total amount of the pharmaceutically active ingredient and the excipient to the water for injection is 5-20: 100.
5. the method according to claim 4, wherein the volume ratio of the total amount of the pharmaceutically active ingredient and the excipient to the water for injection is 8-15: 100.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811560877.0A CN109549931B (en) | 2018-12-18 | 2018-12-18 | Anti-tumor medicine freeze-dried powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811560877.0A CN109549931B (en) | 2018-12-18 | 2018-12-18 | Anti-tumor medicine freeze-dried powder and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109549931A CN109549931A (en) | 2019-04-02 |
| CN109549931B true CN109549931B (en) | 2021-09-24 |
Family
ID=65870655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811560877.0A Active CN109549931B (en) | 2018-12-18 | 2018-12-18 | Anti-tumor medicine freeze-dried powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109549931B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102731396A (en) * | 2011-10-31 | 2012-10-17 | 河北大学 | Polyamine naphthalimide compounds and application of same in preparation of pharmaceutical preparation |
| CN102766103A (en) * | 2012-07-24 | 2012-11-07 | 齐鲁制药有限公司 | 2-sulfo-4-amino-1-naphthol derivative and preparation method and application thereof |
| CN102977125A (en) * | 2011-09-06 | 2013-03-20 | 江苏先声药物研究有限公司 | 2,7-naphthyridine derivative, and preparation method and application thereof |
| CN106279147A (en) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | A kind of pyrido nitrogen heterocyclic and its production and use |
-
2018
- 2018-12-18 CN CN201811560877.0A patent/CN109549931B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102977125A (en) * | 2011-09-06 | 2013-03-20 | 江苏先声药物研究有限公司 | 2,7-naphthyridine derivative, and preparation method and application thereof |
| CN102731396A (en) * | 2011-10-31 | 2012-10-17 | 河北大学 | Polyamine naphthalimide compounds and application of same in preparation of pharmaceutical preparation |
| CN102766103A (en) * | 2012-07-24 | 2012-11-07 | 齐鲁制药有限公司 | 2-sulfo-4-amino-1-naphthol derivative and preparation method and application thereof |
| CN106279147A (en) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | A kind of pyrido nitrogen heterocyclic and its production and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109549931A (en) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60208364T2 (en) | CHINOLINE DERIVATIVES WITH AN AZOLYL GROUP AND CHINAZOLINE DERIVATIVES | |
| US8211911B2 (en) | Compounds as kinase inhibitors | |
| BRPI0805826B1 (en) | spiro-substituted compounds, pharmaceutical composition and use | |
| CN111132984A (en) | Salts of apoptosis signal-regulating kinase 1 inhibitors and crystalline forms thereof | |
| WO2017016463A1 (en) | Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof | |
| WO2020228635A1 (en) | Egfr kinase inhibitor and application thereof in preparing anti-cancer drug | |
| CN109661395A (en) | PDE4 inhibitor | |
| CN112300082B (en) | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | |
| CN106660970A (en) | Quinazoline derivative | |
| CN109846840B (en) | Solid dosage form of vascular endothelial growth factor inhibitor and preparation method thereof | |
| CN109988110B (en) | 4-phenoxy quinoline sulfonylurea compound, intermediate for synthesizing the compound and its preparation method and use | |
| CN108676009A (en) | Pyrimidine derivatives as HER2 tyrosine kinase inhibitors and its application | |
| CN109549931B (en) | Anti-tumor medicine freeze-dried powder and preparation method thereof | |
| CN109535068B (en) | Pyridine substituted chalcone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | |
| WO2020007219A1 (en) | Crystalline form of egfr inhibitor and preparation method therefor | |
| CN109758422B (en) | Small molecule protein kinase inhibitor injection and preparation method thereof | |
| CN107892691B (en) | 2,8, 9-trisubstituted-9H-purine compound and salt and application thereof | |
| CN109651294B (en) | 1, 4-diaminenaphthalene derivative and preparation method and application thereof | |
| US20230322687A1 (en) | Salt of arylaminoquinazoline-containing compound, and preparation method therefor and use thereof | |
| US20230029066A1 (en) | Crystal forms of fused ring compound, and composition thereof, preparation method therefor and application thereof | |
| CN107652275B (en) | Quinazoline derivative and preparation method and application thereof | |
| CN114805304A (en) | 4-methoxyphenyl-1, 3-diamine derivatives containing 1-methyl-1H-indole structure and application thereof | |
| CN110577546B (en) | VEGFR inhibitor and preparation method and application thereof | |
| JP2022517396A (en) | EGFR inhibitor salt, crystalline form and method for producing it | |
| CN111233774B (en) | Amino pyrimidine compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |